Summary: Since joining Amedisys (Nasdaq: AMED) in 2014, CEO Paul Kusserow has spearheaded an ambitious turnaround effort, during which time the company’s stock has climbed from around $20 per share to the more than $130 per share range it sits at today. Most of Amedisys’ growth over the years has come organically, though the Baton Rouge, Louisiana-based company has been active on the M&A front as well, reflected by its two recent hospice deals. Listen to this episode of Disrupt to learn: - What Amedisys is doing to prepare for PDGM - How the company has grown over the last four years - Why Amedisys is becoming an even bigger hospice player - …And much more!
